The use of brincidofovir for the treatment of mixed dsDNA viral infection

Camargo, José F.; Morris, Michele; Abbo, Lilian M.; Simkins, Jacques; Saneeymehri, Seyyedeh; Alencar, Maritza C.; Lekakis, Lazaros J.; Komanduri, Krishna V.

doi:10.1016/j.jcv.2016.07.021

Cited by 28 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cidofovir, a nucleotide analog, has a spectrum of activity that can be considered somewhat broad, with activity against DNA viruses including herpes, polyoma, adeno, and pox viral families. Its less toxic derivative, which remains in development, brincidofovir has been shown to have in vitro activity outside DNA viruses and has been used in the treatment of the RNA-genome filovirus, Ebola, but no human efficacy was noted and it is unclear if in vitro findings were the result of cell toxicity vs. a true antiviral effect [19][20][21] .…”

Section: Antivirals With Broad Spectrum Propertiesmentioning

confidence: 99%

Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool

Adalja

Inglesby

2019

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Section: Antivirals With Broad Spectrum Propertiesmentioning

confidence: 99%

Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool

Adalja

Inglesby

2019

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

“…Brincidofovir is an oral lipid ester prodrug of cidofovir that has demonstrated promising antiviral action against several DNA viruses . It acts in a similar way to cidofovir by competitively inhibiting viral DNA synthesis .…”

Section: Treatment Strategiesmentioning

confidence: 99%

BK virus: Current understanding of pathogenicity and clinical disease in transplantation

Chong

Antoni

Macdonald

et al. 2019

Reviews in Medical Virology

View full text Add to dashboard Cite

BK polyomavirus (BKV) is an important cause of graft loss in renal transplant recipients that continues to pose a significant challenge to clinicians due to its frequently unpredictable onset, persistence, and the lack of effective antiviral agents or prevention strategies. This review covers our current understanding of epidemiology, viral transmission and disease progression, and treatment and prevention strategies that have been used to manage this disease.

show abstract

“…Brincidofovir can be utilized in infections resistant to ganciclovir. Although several case series have shown encouraging results [34,83], a phase III study failed to demonstrate the efficacy of Brincidofovir in the prevention of clinically significant CMV infections in HSCT patients [84].…”

Section: Anti-cmv Novel Agentsmentioning

confidence: 99%

Viral Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Literature Review

Kodad¹,

Sabry²,

Elsayed³

et al. 2019

obm transplant

View full text Add to dashboard Cite

Hematopoietic stem cell transplant (HSCT) recipients are at an increased risk of bacterial, viral, fungal and parasitic infections. Past exposures to infections, the degree of immunosuppression, prolonged neutropenia and presence of graft versus host disease (GVHD) are some of the factors which make HSCT recipients more susceptible to infections. Viral infections have emerged as a major challenge causing high morbidity and mortality in stem cell transplant recipients. Myeloablative conditioning regimens and GVHD prevention strategies which may delay immune reconstitution and serologic status of donors and recipients affect the incidence of viral infections. Community-acquired respiratory and gastrointestinal viral infections like respiratory syncytial virus (RSV), rhinovirus, adenovirus, influenza, norovirus and reactivation of latent viruses like herpes simplex virus (HSV), cytomegalovirus (CMV) are some of the important pathogens increasing the morbidity and mortality in transplant recipients. Clinical manifestations range from asymptomatic carriage to severe disease. Due to lack of effective agents to treat viral infections and emerging resistance patterns, preventive and prophylactic strategies are valuable. Our review article provides an overview of commonly encountered viral infections and their management in an allogeneic stem cell transplant setting in the adult age group. KeywordsViral infections; allogeneic stem cell transplants; hematopoietic stem cell transplants IntroductionViral infections can be asymptomatic or subclinical or even lead to severe disease in allogeneic HSCT recipients. Viral diseases of importance in HSCT include herpes simplex virus (HSV), varicellazoster virus (VZV), human herpesvirus 6 (HHV-6), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and respiratory viruses (eg, respiratory syncytial virus, adenovirus, influenza, parainfluenza). Most of these viral infections are opportunistic in nature and are related to factors influencing engraftment and immune reconstitution [1]. Increase in HLA mismatched donor allogeneic transplants and using anti-thymocyte globulin (ATG) for GVHD prevention are few factors which predispose recipients to viral infections [2,3]. Fortunately, based on molecular diagnostic methods, a polymerase chain reaction can offer an early diagnosis of these infections [4,5]. Early diagnosis facilitates timely intervention controlling infection associated complications. Many prophylactic and pre-emptive treatment strategies are also aimed at decreasing viral infection-related complications [6]. Immunotherapy to restore virus-specific immunity are proven to be effective in treating CMV, EBV and adenovirus infections [7]. In our review article, we have made an attempt to discuss risk factors for post-HSCT viral infections, preventive strategies and treatment options. Risk Factors for Viral Infections Source of Stem CellsPeripheral blood stem cells achieve faster hematopoietic and immune reconstitution compared to bone marrow and cord blood source. Hence, this is asso...

show abstract

The use of brincidofovir for the treatment of mixed dsDNA viral infection

Cited by 28 publications

References 16 publications

Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool

Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool

BK virus: Current understanding of pathogenicity and clinical disease in transplantation

Viral Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Literature Review

Contact Info

Product

Resources

About